Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas

American Journal of Clinical Pathology

Volumn 123, Issue 6, 2005, Pages 900-906

  Alonso, M Eva ^a   Bello, M Josefa ^a   Arjona, Dolores ^a   Martinez Glez, Victor ^a   De Campos, Jose M ^a   Isla, Alberto ^b   Kusak, M Elena ^a   Vaquero, Jesús ^c   Gutierrez, Manuel ^b   Sarasa, Jose L ^d   Rey, Juan A ^a,b  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

CDK4; Gene amplification; MDM2; Oligodendroglioma

Indexed keywords

CYCLIN DEPENDENT KINASE 4; GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN MDM2; PROTEIN MDMX; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DOSAGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WORLD HEALTH ORGANIZATION;

EID: 21144436493     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/448YRWNC43TE32KQ     Document Type: Article

References (36)

1. Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000, World Health Organisation Classification of Tumours.
2. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p, Am J Pathol. 1994;145:1175-1190.
3. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer. 1995;64:207-210.
4. Sasaki H, Zlatescu MC, Betensky RA, et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159:359-367.
5. Bortolotto S, Chiado-Piat L, Cavalla P, et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer. 2000;88:554-557.
6. Dong SM, Pang JCS, Poon WS, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol. 2001;60:808-816.
7. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet. 2003;144:134-142.
8. Collins VP. Gene amplification in human gliomas. Glia. 1995;15:289-296.
9. Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 1994;54:4299-4303.
10. Fisher U, Meltzer P, Meese E. Twelve amplified and expressed genes localized in a single domain in gliomas. Hum Genet. 1996;98:625-628.
11. Reifenberger G, Ichimura K, Reifenberger J, et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. 1996;156:5141-5145.
12. Kawai H, Wiederschain D, Kitao H, et al. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem. 2003;278:45946-45953.
13. Riemenschneider MJ, Büschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q12 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999;59:6091-6096.
14. Reifenberger G, Prior R, Deckert M, et al. Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system. Virchows Arch A Pathol Anat Histopathol. 1989;414:147-155.
15. Yu D, Hung MC. Overexpression of erbB2 in cancer and erbBZ-targeting strategies. Oncogens, 2000;19:6115-6121.
16. Dai C, Celestino JC, Okada Y, et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001;15:1913-1925.
17. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol. 2000;59:495-503.
18. Kim YR, Choi JR, Song KS, et al. Evaluation of HER2/neu status by real-time quantitative PCR in breast cancer. Yonsei Med J. 2002;43:335-340.
19. Tajiri T, Tanaka S, Shono K, et al. Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett. 2001;166:89-94.
20. I cyclins. Cell. 1993;73:1059-1065.
21. Rolbrocker B, Waha A, Louis DN, et al. Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol. 1996;92:70-74.
22. Sato K, Schauble B, Kleihues P, et al. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in nonastrocytic human brain tumors. Int J Cancer. 1996;66:305-308.
23. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res, 1998;26:3453-3459.
24. Perry A, Anderl K, Borell TJ, et al. Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am J Clin Pathol. 1999;112:801-809.
25. Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutation. Cancer Res. 1993;53:2736-2739.
26. Riemenschneider MJ, Knobbe CB, Reifenberger G. Refined mapping of 1p32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer, 2003;104:752-757.
27. Almeida A, Zhu XX, Vogt N, et al. GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1 is amplified and overexpressed in malignant gliomas. Oncogens. 1998;16:2997-3002.
28. Ariza A, Fernandez LA, Inagami T, et al. Renin in glioblastoma multiforme and its role in neovascularization. Am J Clin Pathol. 1988;90:437-441.
29. Andreoli JM, Jang SI, Chung E, et al. The expression of a novel epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. Nucleic Acids Res. 1997;25:4287-4295.
30. Oettgen P, Barcinski M, Boltax J, et al. Genomic organization of the human ELF3 (ESE-1/ESX) gene a member of the Ets transcription factor family and identification of a functional promoter. Genomes. 1999;55:358-362.
31. Janknecht R, Nordheim A. Gene regulation by Ets proteins. Biochim Biophys Acta. 1993;1155:346-356.
32. Galang CK, MullerWJ, Foos G, et al. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem. 2004;279:11281-11292.
33. Yu D, Matin A, Xia W, et al. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogens. 1995;11:1383-1388.
34. Lear-Kaul KG, Yoon H-R, Kleinschmidt-DeMasters BK, et al. HER-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med. 2003;127:1451-1457.
35. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 1983;303:390-396.
36. Guha A, Dashner K, Black PM, et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 1995;60:168-173.